Apoptosis is the death of cell in a programmed fashion that is observed largely in multicellular organisms. This programmed cell death occurs in a cascade of biochemical events which include blebbing, cell shrinkage, nuclear fragmentation, chromatin condensation and chromosomal fragmentation. Anywhere between 50 and 70 billion cells die each day due to apoptosis in the average human adult. This cascade has been hypothesized to be exploited as an ideal method of anti-cancer strategy traditionally by inducing DNA damage with chemotherapy and radiotherapy. 
These methods have been the backbone of most anti-cancer therapies today, but with increasing knowledge of intrinsic and extrinsic pathways of apoptosis, innovative apoptotic agents have been under investigation since the past several years. There are currently several of these agents in clinical trials for potential role in cancer therapeutics and are expected to become another weapon in our arsenal for the fight against cancer. In technical process death receptors CD95, death receptor DR4 and DR5 along with tumor necrosis factor receptor 1 TNFR1 can effectively induce apoptosis when bound by their ligands. Significant evidence obtained in several animal models confirms the validity of strategies for targeted apoptosis and has revealed an enormous potential for therapeutic intervention in a variety of illnesses. Almost all key participant proteins in cellular apoptosis regulation have been identified and can be targeted by therapeutic strategies which include above mentioned death receptors, Bcl-2 proteins, caspases, endogenous caspase inhibitors and transcriptional regulators. 
The current scenario is quite challenging with greater restraints than drivers due to low success ratio. The superior tumor killing activity of TRAIL agonists and the toxic side effects associated with systemic treatment of other death ligands. In animal models a great degree of success was achieved for treatment against inflammatory bowel disease with the help of anti-TNF antibodies or genetic TNF knockout. WHO predicted that annual cancer cases will reach to 19.3 million by 2025 from the 14.1 million annually in year 2012.  There were 8.2 million deaths from cancer in the world in 2012 according to cancer research U.K. More than 60% of world’s total new annual cases occur in Africa, Asia and Central and South America. These regions account for 70% of the world’s cancer deaths. This also represents a sizable opportunity for innovative cancer therapeutics companies worldwide. Current economic scenario indicates an improving purchase power and increasing investment in healthcare in developing countries which also governs the fact that emerging players in this arena can profit considerably contrary to conventional observations that profit can be gained only from developed regions such as North America and Europe.
Current companies that are involved in the research and development of targeted apoptosis therapeutics include Genentech and Amgen are in the process of conducting phase-1 clinical trials for soluble TRAIL agonists as anti-cancer agents. An agonistic TRAIL-R2 antibody (TRA-8) was generated by Sankyo Co., Ltd. (Tokyo, Japan) and proved to be cytotoxic against primary hepatocellular carcinoma cells without inducing cell death in normal hepatocytes. Human Genome Sciences Inc. has recently enrolled patients in phase 2 clinical trials with the TRAIL-R1-specific human monoclonal antibody HGS-ETR1 for the treatment of nonsmall cell lung cancer, colorectal carcinoma, and non-Hodgkin lymphoma. According to the study, approximately six of 57 patients enrolled even reached a stable disease situation. GlaxoSmithKline disclosed a series of similar piperidinyl substituted isatins and related 5-alkylaminosulphonyl-3,3-dichloro-oxindoles. With this, Pfizer has also continued research in caspase inhibitors such as isatin-based caspase inhibitors, from which the compound MMPSI, a (2-methoxymethylpyrrolidinyl)-sulfonylisatin, was able to reduce ischemic injury. This can also be used in targeted apoptosis for cancers. Several Merck inhibitors are currently in preclinical trials.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Apoptotic Therapeutics Oncology Market

Pre Book